Androgen receptor/let-7a signaling regulates breast tumor-initiating cells
Metrics: PDF 1270 views | HTML 2024 views | ?
Wei Zhang1,2,3,*, Xiaozhen Liu1,*, Shan Liu1, Ying Qin1, Xiaoqi Tian1, Fengting Niu1, Han Liu1, Ning Liu4 and Yun Niu1
1Department of Breast Cancer Pathology and Research, National Clinical Cancer Research Center, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University, Tianjin, China
2Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China
3Laboratory of Epigenetics and Tumorigenesis, Tianjin Research Center of Basic Medical Sciences, Tianjin Medical University, Tianjin, China
4Department of Pathology, Baodi Clinical Institute of Tianjin Medical University, Tianjin, China
*These authors contributed equally to this work
Yun Niu, email: [email protected]
Keywords: breast cancer; androgen receptor; let-7a; tumor-initiating cells; CD44+/24-/low
Received: October 19, 2017 Accepted: December 01, 2017 Published: December 08, 2017
Androgen receptor (AR) is an important transcriptional factor, which is frequently expressed in invasive breast cancer and correlates patients’ prognosis. Our previous results indicate AR activation may increase let-7a expression in breast cancer cells, while let-7, a tumor suppressor, is reported to inhibit breast tumor-initiating cells (T-IC). The study aims to explore the effects of AR/let-7a signaling on breast T-IC and its regulatory mechanism. The results revealed that the expression of AR was significantly associated with let-7a and CD44+/24-/low especially in estrogen receptor positive (ER+) breast cancer tissues. The expression of AR and let-7a indicated better outcome, while patients with CD44+/24-/low phenotype had worse prognosis. AR activation induced by dihydrotestosterone (DHT) prevented cells proliferation, migration, invasion and self-renewal capacities in ER+ breast cancer cells, via transcriptional up-regulation of let-7a. In addition, AR could inhibit tumorigenesis and metastasis of ER+ breast cancer cells in the serial xenotranplanted animal models. Our data suggested that AR/let-7a signaling could inhibit the biological behavior of tumor-initiating cells (T-IC) in ER+AR+ breast cancers, which might become a new therapeutic target.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.